Navigation Links
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Date:2/4/2008

HORSHAM, Pa., Feb. 4 /PRNewswire/ -- Centocor, Inc. announced today that the Biologics License Application (BLA) for ustekinumab (CNTO 1275) has been accepted for review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic moderate to severe plaque psoriasis. Ustekinumab is a new, human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), naturally occurring proteins that are important in regulating immune responses and that are thought to be associated with some immune-mediated inflammatory disorders, including psoriasis.

"We are pleased by the FDA's acceptance of our Biologics License Application for review of ustekinumab," stated Jerome A. Boscia, M.D., senior vice president, Clinical R&D, Centocor, Inc. "Ustekinumab has yielded promising efficacy and safety results in Phase 3 clinical trials, and we look forward to working closely with the FDA during their ongoing review of this potential new treatment for psoriasis."

Centocor, Inc. announced that it had submitted the BLA for ustekinumab in December 2007 based on its comprehensive development program including data from two large Phase 3 multicenter, randomized, double-blind, placebo- controlled trials involving nearly 2,000 patients that evaluated the safety and efficacy of ustekinumab in the treatment of moderate to severe plaque-type psoriasis. The primary endpoint of both studies was the proportion of patients who achieved at least a 75 percent reduction in psoriasis as measured by the Psoriasis Area and Severity Index (PASI 75). Acceptance of the BLA filing does not mean that a license has been issued for this product nor does it represent any evaluation of the adequacy of the data submitted in the BLA. In December 2007 the Marketing Authorization Application (MAA) for ustekinumab was submitted in Europe and is currently under review by the European Medicines Agency (
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... The fully automated supercritical fluidic chromatography-based ... analyze up to 48 samples utilizing automatic extraction ... targets by mass spectrometry. , The Nexera ... requirements of a wide range of applications, including ... search for disease biomarkers, additives in forming polymers, ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Cytokinetics, ... forces on February 28 with patients and health care ... awareness for Rare Disease Day®. Rare Disease Day ... and calling attention to the special challenges faced by ... them. , “Cytokinetics is proud to stand alongside patients ...
(Date:2/26/2015)... 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a significant ... Inc. in excess of $10 million. The jury determined ... and that it improperly hired one or more of ... for judgment notwithstanding the verdict, a new trial, and ...
(Date:2/26/2015)... 2015   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... Chief Executive Officer of Regulus, will present a company ... Annual Healthcare Conference on Wednesday, March 4, 2015 at ... the Boston Marriott Copley Place.  The ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... ... has recently gained popularity for treatment of fungal nails. OnychoLase™ Laser Nail ... “prescreening” practioners and making sure that they satisfy the requirements to bear the brand ... , ...
... Silence Therapeutics plc (AIM: SLN) ("Silence" ... States patent 7,723,316, titled Compositions and Methods of ... Disease, by the United States Patent and Trademark Office ... portfolio of RNA interference (RNAi) intellectual property, is broadly ...
... 2010 Hailed as a "cross between a high-speed ... have developed a new, practical technology for fabricating tiny ... Badrossamay to the fairground treat of spun sugar is ... and pushes out 100 nanometer-diameter polymer-based threads using a ...
Cached Biology Technology:OnychoLase™ Laser Nail Center Provides New Laser Nail Therapy to Help Fight Against Fungal Nails 2OnychoLase™ Laser Nail Center Provides New Laser Nail Therapy to Help Fight Against Fungal Nails 3Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 2Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 3Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States 4Inspired by a cotton candy machine, engineers put a new spin on creating tiny nanofibers 2Inspired by a cotton candy machine, engineers put a new spin on creating tiny nanofibers 3
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... to decisions about land use than climate change, population ... Mountains of Morocco, individual religious beliefs in local Saints ... use their environment and manage local resources. These findings1 ... Barcelona in Spain, and his colleagues, published online in ...
... call it comparing apples and oranges, but lining up ... Scientists can see how species have evolved, pinpoint which ... probably are crucial to the animals, survival, or sketch ... is spotty. , But the tools used to align ...
... Ore. Researchers at Oregon State University have made an ... toward robots that not only can walk and run effectively, ... an optimal approach with robotic mechanisms, studies are moving closer ... military, create prosthetic limbs for humans that work much better, ...
Cached Biology News:Farmers' beliefs on a higher plain 2Genome comparison tools found to be susceptible to slip-ups 2Advances made in walking, running robots 2Advances made in walking, running robots 3
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Pendrin (H-195)...
Biology Products: